EDAP Announces FDA Breakthrough Device Designation for Focal One® in the Treatment of Deep Infiltrating Rectal Endometriosis.

https://finance.yahoo.com/news/edap-announces-fda-breakthrough-device-120000865.html

Synchronoss (NASDAQ $9.58) is one of my favorite stocks for 2024. It have been a dog for the last few years, but things have changed. Q4 (to be reported March 12th), will be ugly, as they sold off part of the company and whacked $10-$15 million of expenses, but I expect guidance to be good. I am expecting revenues for 2024 of around $170 million. This is all high margin SAAS revenue. I expect EPS around $1.50 a share for the year. Anything under $10 is a good buying area. Hopefully on the 12th, they will give guidance in this vicinity. If they do, I am looking for at least $15 a share for a 50% gain from here.